Evidence map›Paper›PMID 35769562›Full record

ArticleFrontiers in allergy2022

Reconciling Allergy Information in the Electronic Health Record After a Drug Challenge Using Natural Language Processing.

Ying-Chih Lo, Sheril Varghese, Suzanne Blackley, Diane L Seger, Kimberly G Blumenthal, Foster R Goss, Li Zhou

Open access · goldAbstract read
In one paragraph

Article in Frontiers in allergy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Ying-Chih LoDivision of General Internal Medicine and Primary Care, Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States.
Sheril VargheseDivision of General Internal Medicine and Primary Care, Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States.
Suzanne BlackleyMass General Brigham, Boston, MA, United States.
Diane L SegerDivision of General Internal Medicine and Primary Care, Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States.
Kimberly G BlumenthalHarvard Medical School, Boston, MA, United States.
Foster R GossDepartment of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, United States.
Li ZhouDivision of General Internal Medicine and Primary Care, Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States.
Brigham and Women's Hospital · USMass General Brigham · USHarvard University · USUniversity of Colorado Denver · US

Funding

Clinical Informatics to Advance Epidemiology and Pharmacogenetics of Serious Cutaneous Adverse Drug ReactionsR01AI150295 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI ZHOU, LI · 2019 to 2022
$2.8M
Improving Allergy Documentation and Clinical Decision Support in the EHRR01HS025375 · AHRQ · BRIGHAM AND WOMEN'S HOSPITAL · PI ZHOU, LI · 2018 to 2021
$1.6M
AHRQ HHS R01 HS025375NIAID NIH HHS R01 AI150295
6 · The paper itself

Abstract

Background: Drug challenge tests serve to evaluate whether a patient is allergic to a medication. However, the allergy list in the electronic health record (EHR) is not consistently updated to reflect the results of the challenge, affecting clinicians' prescription decisions and contributing to inaccurate allergy labels, inappropriate drug-allergy alerts, and potentially ineffective, more toxic, and/or costly care. In this study, we used natural language processing (NLP) to automatically detect discrepancies between the EHR allergy list and drug challenge test results and to inform the clinical recommendations provided in a real-time allergy reconciliation module. Methods: This study included patients who received drug challenge tests at the Mass General Brigham (MGB) Healthcare System between June 9, 2015 and January 5, 2022. At MGB, drug challenge tests are performed in allergy/immunology encounters with routine clinical documentation in notes and flowsheets. We developed a rule-based NLP tool to analyze and interpret the challenge test results. We compared these results against EHR allergy lists to detect potential discrepancies in allergy documentation and form a recommendation for reconciliation if a discrepancy was identified. To evaluate the capability of our tool in identifying discrepancies, we calculated the percentage of challenge test results that were not updated and the precision of the NLP algorithm for 200 randomly sampled encounters. Results: Among 200 samples from 5,312 drug challenge tests, 59% challenged penicillin reactivity and 99% were negative. 42.0%, 61.5%, and 76.0% of the results were confirmed by flowsheets, NLP, or both, respectively. The precision of the NLP algorithm was 96.1%. Seven percent of patient allergy lists were not updated based on drug challenge test results. Flowsheets alone were used to identify 2.0% of these discrepancies, and NLP alone detected 5.0% of these discrepancies. Because challenge test results can be recorded in both flowsheets and clinical notes, the combined use of NLP and flowsheets can reliably detect 5.5% of discrepancies. Conclusion: This NLP-based tool may be able to advance global delabeling efforts and the effectiveness of drug allergy assessments. In the real-time EHR environment, it can be used to examine patient allergy lists and identify drug allergy label discrepancies, mitigating patient risks.

Indexed as

clinical decision support system (CDSS)drug challenge testelectronic health record (EHR)medication reconciliationnatural language processing

Identifiers

PMID35769562
PMCPMC9234873
OpenAlexW4229458456

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.